Medicines: Ivosidenib

0:01:48

IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML

0:03:39

Ivosidenib plus azacitidine for mIDH1 newly diagnosed AML

0:01:14

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

0:02:42

Final results from ClarIDHy: ivosidenib in IDH1-mutated CCA

0:00:47

Dr. Winer Discusses the FDA Approval of Ivosidenib in AML

0:06:52

Ivosidenib and venetoclax +/- azacitidine for IDH1-mutated hematologic malignancies

0:07:24

What are the side effects of ivosidenib? #AML

0:00:59

AML: ivosidenib is coming

0:04:38

Curtis Andrew Lachowiez: Ivosidenib + Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies

0:02:54

Cost-effectiveness of azacitidine and ivosidenib in elderly patients with newly diagnosed IDH1m AML

0:07:20

Treating patients with Enasidenib or Ivosidenib: Managing IDH-DS & other Clinical Pearls

0:03:01

FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for adult patients with previo...

0:04:54

ClarIDHy: Targeted therapy ivosidenib for advanced cholagiocarcinoma

0:02:49

AML post-transplant maintenance: enasidenib & ivosidenib

0:01:32

IDIOME: ivosidenib in IDH1 mutant MDS

0:08:00

ClarIDHy Phase III Trial of Ivosidenib in CCA

0:05:02

Results from AGILE: ivosidenib-azacitidine vs azacitidine-placebo in patients with IDH1m AML

0:01:37

Comment: Targeted therapy ivosidenib in cholagiocarcinoma

0:03:48

Assist. Prof. Courtney DiNardo | ASH 2017 | Ivosidenib in IDH1 AML

0:03:47

What is ivosidenib? #AML

0:03:31

FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or ...

0:02:52

Ivosidenib or enasidenib with chemotherapy for AML produces deep remissions

0:00:50

Update on the PIMMs trial of ivosidenib for patients with IDH1-mutated CCUS

0:05:47

IDH1/2 Inhibitors for AML